Semaglutide's origin: from Gila monster venom to a licensed UK weight-loss medicine

The biological starting point: a hormone the gut already makes

To understand semaglutide's origin, it helps to start with the hormone it mimics. GLP-1 is secreted by specialised cells in the small intestine within minutes of eating. It signals the pancreas to release insulin, tells the brain that food has arrived, slows how quickly the stomach empties, and reduces the urge to keep eating. The problem is that GLP-1 has an extremely short half-life, natural enzymes called DPP-4 degrade it within two to three minutes of release, before it can have a sustained effect.

That brief window is why early researchers were excited by exendin-4, a 39-amino-acid peptide found in the saliva of the Gila monster (Heloderma suspectum) in the late 1980s. The discovery, led by endocrinologist John Eng at the Veterans Affairs Medical Center in New York, showed that exendin-4 binds the GLP-1 receptor and activates it in almost the same way as the human hormone, but resists the DPP-4 enzyme that normally destroys GLP-1 so quickly. That resistance made it last hours rather than minutes. It became the template for a whole class of medicines. You can read more about what semaglutide was originally developed to treat and how its therapeutic scope broadened over time.

Novo Nordisk took this research further, engineering semaglutide specifically to last a full week. They attached a fatty-acid chain to the GLP-1 analogue backbone, which allows it to bind to albumin proteins in the blood and be released gradually. That weekly durability is what makes a once-weekly injection clinically practical, and it is the structural feature that sets semaglutide apart from earlier, shorter-acting GLP-1 medicines.

From the diabetes clinic to a dedicated obesity programme

Semaglutide's first licensed indication was type 2 diabetes, where it was approved under the brand name Ozempic. The diabetes trials revealed something clinically striking: participants were losing meaningful amounts of body weight as a side effect of the glucose-lowering treatment. That observation prompted Novo Nordisk to run a dedicated obesity programme, the STEP trials, using a higher 2.4mg maintenance dose rather than the diabetes doses.

The results shaped the medicine's regulatory history in the UK. The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with obesity or overweight plus at least one weight-related condition who did not have type 2 diabetes. Over 68 weeks, participants receiving semaglutide 2.4mg alongside lifestyle support lost around 15% of their body weight on average, compared with around 2.4% in the placebo group. Those figures persuaded regulators that a dedicated weight-management licence was justified. The UK's MHRA granted that licence, Wegovy became available here, and NICE subsequently recommended it under specific criteria for NHS use.

It is worth pausing on the scale of what that regulatory process involves. The STEP programme ran across multiple countries, different populations and varying comorbidity profiles. The name Wegovy itself was chosen separately from Ozempic to signal a distinct clinical purpose, even though the active molecule is the same semaglutide. The distinction matters: Ozempic is not licensed for weight management in the UK, and the two should not be conflated.

What the evidence base tells us about semaglutide's mechanism in practice

The clinical evidence, anchored in the STEP programme and reviewed by NICE in its appraisal of semaglutide (TA875), confirms that semaglutide works through three main pathways simultaneously: reducing appetite by acting on receptors in the hypothalamus, slowing gastric emptying so meals feel more satisfying for longer, and improving the body's response to insulin. None of these effects is cosmetic; they reflect genuine changes in physiology rooted in GLP-1 biology.

The MHRA approved a higher 7.2mg maintenance dose for Wegovy in January 2026, and a dedicated single-dose 7.2mg pen was approved on 14 April 2026, a development that brought trial-reported average weight loss of around 20.7% over 72 weeks at that dose closer to the results seen with tirzepatide. That trajectory, from a reptile peptide to incrementally refined doses targeting increasingly meaningful clinical outcomes, reflects how the origin story keeps extending rather than concluding.

For anyone considering semaglutide for weight management, understanding where the molecule comes from also clarifies why it behaves as it does: the GI side effects (nausea, reduced appetite, early fullness) are not incidental, they are direct consequences of the GLP-1 pathway the medicine was designed to engage. Our full semaglutide guide covers the side-effect profile and what to expect during the titration schedule in more detail. If timing matters to you (many people plan their first order around a quieter week rather than, say, a busy holiday period) a free consultation lets you work that through with a prescriber before anything is dispensed.

Semaglutide's origin and what it means for UK patients today

The practical takeaway from semaglutide's origin is that this is not a new or experimental compound repurposed hastily. By the time Wegovy reached UK pharmacies, the GLP-1 receptor agonist class had more than a decade of real-world safety data from diabetes practice, and semaglutide specifically had been studied in cardiovascular and liver-disease trials beyond the obesity programme. The MHRA's conditional approval of Wegovy for a form of fatty liver disease (MASH) in July 2026 is a direct extension of that research lineage.

In the UK, Wegovy is a prescription-only medicine, which means a prescriber must assess clinical suitability before it can be issued. That assessment covers medical history, current medicines, weight-related conditions and BMI, and patients who hold AXA health insurance may find specific guidance on how Wegovy is covered under their policy useful before beginning that conversation. The country where Wegovy is manufactured and the supply chain it travels through also matter, because counterfeit versions of weight-loss pens do circulate online. The MHRA has warned explicitly about fake pens that have contained the wrong active substance entirely. Sourcing from a pharmacy verifiable on the GPhC register is the straightforward way to confirm you are receiving the genuine, licensed product.

If you are exploring whether semaglutide is clinically appropriate for you, our free consultation with a GPhC-registered prescriber is a sensible starting point. There is no obligation, and the clinical review is the same day for orders placed before midday.